Patent · US Active

Heteroarylbenzimidazole compounds

US10894784B2 · kind B2 · utility

0Cited by

0References

15Claims

0Family size

Assignee

Bayer Pharma Aktiengesellschaft · DE

Inventors

Volker Schulze · Hohen Neuendorf, DE
Tobias Heinrich · Berlin, DE
Florian Prinz · Berlin, DE
Julien LEFRANC · Berlin, DE
Jens SCHRÖDER · Jena, DE
Anne Mengel · Berlin, DE
Wilhelm Bone · Berlin, DE
Joszef Bálint · Berlin, DE
Antje Margret Wengner · Berlin, DE
Knut Eis · Berlin, DE
Horst IRLBACHER · Berlin, DE
Marcus Koppitz · Berlin, DE
Ulf Bömer · Glienicke, DE
Benjamin Bader · Berlin, DE
Hans Briem · Bremen, DE
Philip Lienau · Berlin, DE
Clara Christ · Leverkusen, DE
Detlef STÖCKIGT · Potsdam, DE
Roman Hillig · Berlin, DE

Key dates

Filing date	Dec 15, 2016
Grant date	Jan 19, 2021
Priority date	—
Expiry date	Dec 15, 2036

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D487/08
WIPO fieldOrganic fine chemistry
WIPO sectorChemistry

Abstract

The present invention covers heteroarylbenzimidazole compounds of general formula (I) in which R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative and/or inflammatory disorders, as a sole agent or in combination with other active ingredients.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.